With no acute outbreak or regulatory shockwave this week, the most actionable story is consumer curiosity: PCOS topped the Emerging Demand Index at 2.61, driven almost entirely by a 45% week-over-week jump in Wikipedia pageviews. Ketamine therapy followed at 1.96 on a similar mechanism. Both are attention-led signals — not news-driven, not regulatory — which historically translate into a 2-4 week lag before search and intake calls move.

Emerging Demand — What to Watch

  • PCOS — EDI 2.61. Wikipedia pageviews +45% WoW with no offsetting trials or FDA catalyst. Pure consumer-attention signal feeding Endocrinology and Women's Health. Watch for downstream lift in metformin and GLP-1 off-label queries.
  • Ketamine therapy — EDI 1.96. Wikipedia pageviews +34% WoW. No new FDA action, suggesting the spike is media- or influencer-driven rather than regulatory. Mental health clinics should expect inbound inquiries before paid search CPCs catch up.
  • Sciatica — EDI 0.54. Wikipedia pageviews +10% WoW. Modest but consistent — a coincident pain-management signal worth watching for orthopedic and PT capacity.
  • Endometriosis — EDI 0.47. Wikipedia pageviews +13% WoW alongside 5 new recruiting trials in the last 30 days. Two-source confirmation (consumer + research pipeline) makes this the most structurally interesting signal on the board.
  • Wegovy — EDI 0.44. Wikipedia pageviews +5% WoW plus a fresh FDA approval action on WEGOVY. The mechanism here is regulatory — the consumer signal is muted, but the supply-side news typically pulls demand forward 1-2 weeks.

Search Intent

No conditions are rising on Google Trends nationally this week — a notable absence given the EDI heat on PCOS and ketamine. That gap is the leading-indicator window: Wikipedia is moving before Google is. COVID symptoms searches fell 19% (recent 4-week avg of 6 vs prior 8), continuing the post-March spike normalization. High blood pressure queries dropped 14% (65 vs 75), a seasonal softening as the late-winter cardiology rush fades.

Structural Markets

With no fresh BRFSS state deltas surfacing this week, the structural read defaults to the trial pipeline: 18 new recruiting depression trials and 16 new obesity trials in the last 30 days point to sustained pharma investment in psychiatry and bariatrics — relevant for clinics positioning around clinical-trial referral revenue or post-trial patient capture.

The Bottom Line

This is a Wikipedia-led week — meaning operators in women's health (PCOS, endometriosis) and mental health (ketamine) should pre-load ad budget and intake staffing now, before Google Trends confirms in 2-3 weeks. If you run a weight-loss clinic, the Wegovy FDA action is your cue to refresh creative this week. Everyone else: respiratory is quiet, hypertension search is cooling, and there's no acute surge to chase.